Is Apogee Therapeutics, Inc. (APGE) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 10.4% / 30% | 0.1% / 30% | N/A | ✓ HALAL |
| DJIM | 0.2% / 33% | 10.4% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| MSCI | 1.6% / 33% | 69.1% / 33% | 0.6% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 10.4% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| FTSE | 1.6% / 33% | 69.1% / 33% | 0.6% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -31.6% | |
| Return on Assets (ROA) | -21.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$227M |
| Free Cash Flow | -$233M |
| Total Debt | $9M |
| Debt-to-Equity | 1.0 |
| Current Ratio | 26.6 |
| Total Assets | $937M |
Price & Trading
| Last Close | $78.42 |
| 50-Day MA | $71.24 |
| 200-Day MA | $56.48 |
| Avg Volume | 962K |
| Beta | 1.4 |
|
52-Week Range
$26.20
| |
About Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Apogee Therapeutics, Inc. (APGE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Apogee Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Apogee Therapeutics, Inc.'s debt ratio?
Apogee Therapeutics, Inc.'s debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.6%.
What are Apogee Therapeutics, Inc.'s key financial metrics?
Apogee Therapeutics, Inc. has a market capitalization of $5.8B. Return on equity stands at -31.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.